This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bienvenu, A.-L.
Right arrow Articles by Picot, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bienvenu, A.-L.
Right arrow Articles by Picot, S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2008, p. 4203-4204, Vol. 52, No. 11
0066-4804/08/$08.00+0     doi:10.1128/AAC.00513-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

LETTER TO THE EDITOR

Statins Alone Are Ineffective in Cerebral Malaria but Potentiate Artesunate{triangledown}


arrow
LETTER
 
Statins are a family of lipid-lowering drugs widely used to control the cholesterol level and to prevent stroke and cardiac failure in patients at high risk of coronary artery disease. Recently, statins demonstrated pleiotropic cholesterol-independent effects (2). Used after stroke, statins proved to be neuroprotective in the setting of cerebral ischemia, with improved functional outcome in patients (5). Used after septic insult, statins demonstrated increased survival time due to restoration of cardiac function and haemodynamic status (4). These effects occur before cholesterol lowering and without pretreatment. According to these benefits, we postulate that statins could be considered as new potential drugs during acute cerebral infectious diseases. Among these, cerebral malaria due to Plasmodium falciparum is still one of the worst killers in tropical countries. Considering the role of inflammatory and ischemic injuries during cerebral malaria, we addressed the place of statins as emergency treatment in a clinically relevant murine model.

Statins differ in terms of their chemical structures, pharmacokinetic profiles, and lipid-modifying efficacy (7). As differences could be expected in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition, several statins were tested for neuroprotective potential. The effects of pravastatin, fluvastatin, simvastatin, and atorvastatin were compared to the neuroprotective effect of erythropoietin, known to provide 60% survival in an experimental model of cerebral malaria (3). Pravastatin and fluvastatin were administrated at high doses (40 to 200 mg/kg of body weight), simvastatin at 40 mg/kg, and atorvastatin at 20 mg/kg, once per day for three to five days at the onset of the disease. Surprisingly, all statins used alone failed to prevent death from cerebral malaria (Table 1), and this raised questions for the scientific community during a recent meeting (1). Despite the in vitro antimalarial effect of atorvastatin described by Pradines et al. (6), none of these statins showed an effect on parasitemia in mice when used at the same range of doses as the concentrations used in vitro (20 to 300 µM). There is a growing body of literature suggesting that the pleiotropic effects of statins may be useful in a wide range of indications, including poststroke reperfusion, septic insult, anticancer drug resistance, and inflammatory rheumatoid diseases.


View this table:
[in this window]
[in a new window]

  		TABLE 1. Treatment of mice presenting cerebral malaria with statins under different regimensa

While statins failed to prevent death, it could be speculated that they could act as an adjuvant therapy. Mice were treated with a drug combination of artesunate and atorvastatin under the same conditions as described above, and we observed a significant improvement in survival at day 13 postinfection compared to survival with atorvastatin alone (P < 0.02; log rank test, cumulative survival analysis) (Fig. 1).


Figure 1
View larger version (13K):
[in this window]
[in a new window]

  		FIG. 1. Univariate analysis of survival (SPSS 11.5). Benefit of the drug combination artesunate-atorvastatin for survival compared to atorvastatin treatment alone. The results of the log rank test revealed that artesunate-atorvastatin given from day 4 to day 6 postinfection had an effect on survival (P < 0.02). AS, artesunate; ATV, atorvastatin.

Considering sepsis, we speculated that statins could be a panacea (8). In the light of our observations during cerebral malaria, this new paradigm should rather be reconsidered as an adjuvant effect. As pleiotropic effects may largely depend on the pathophysiology of the respective disease and on the patient's status, convincing clinical trials are needed to explore the scope of these drugs. The safety of statins when administrated after the insult also needs to be addressed, since these molecules were not originally designed for these therapeutic approaches.

(This work was presented in part at the Annual Meeting of the American Society of Tropical Medicine and Hygiene, Philadelphia, PA, 2007.)


arrow
ACKNOWLEDGMENTS
 
We are particularly grateful to Novartis Pharma AG Stein and Merck Research Laboratory for kindly providing fluvastatin and simvastatin, respectively. Special thanks to B. Pradines and T. Fusai (IMTSSA, Marseilles, France) for their gift of atorvastatin and for helpful discussions.

We declare that we have no conflict of interest.


arrow
FOOTNOTES
 
{triangledown} Published ahead of print on 8 September 2008. Back


arrow
REFERENCES
 
    1
  1. Bienvenu, A. L., J. Ferrandiz, D. Autheman, and S. Picot. 2007. Statins failed to protect mice from cerebral malaria, abstr. 2727. Abstr. 56th Annu. Meet. Am. Soc. Trop. Med. Hyg.
    2. 2
  2. Corsini, A., N. Ferri, and M. Cortellaro. 2007. Are pleiotropic effects of statins real? Vasc. Health Risk Manag. 3:611-613.[Medline]
    3. 3
  3. Kaiser, K., A. Texier, J. Ferrandiz, A. Buguet, A. Meiller, C. Latour, F. Peyron, R. Cespuglio, and S. Picot. 2006. Recombinant human erythropoietin prevents the death of mice during cerebral malaria. J. Infect. Dis. 193:987-995.[CrossRef][Medline]
    4. 4
  4. Merx, M. W., E. A. Liehn, J. Graf, A. van de Sandt, M. Schaltenbrand, J. Schrader, P. Hanrath, and C. Weber. 2005. Statin treatment after onset of sepsis in a murine model improves survival. Circulation 112:117-124.[Abstract/Free Full Text]
    5. 5
  5. Moonis, M., K. Kane, U. Schwiderski, B. W. Sandage, and M. Fisher. 2005. HMG-CoA reductase inhibitors improve acute ischemic stroke outcome. Stroke 36:1298-1300.[Abstract/Free Full Text]
    6. 6
  6. Pradines, B., M. Torrentino-Madamet, A. Fontaine, M. Henry, E. Baret, J. Mosnier, S. Briolant, T. Fusai, and C. Rogier. 2007. Atorvastatin is 10-fold more active in vitro than other statins against Plasmodium falciparum. Antimicrob. Agents Chemother. 51:2654-2655.[Free Full Text]
    7. 7
  7. Schachter, M. 2005. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam. Clin. Pharmacol. 19:117-125.[CrossRef][Medline]
    8. 8
  8. Terblanche, M., Y. Almog, R. S. Rosenson, T. S. Smith, and D. G. Hackam. 2007. Statins and sepsis: multiple modifications at multiple levels. Lancet Infect. Dis. 7:358-368.[CrossRef][Medline]
Anne-Lise Bienvenu*
Stéphane Picot
University Lyon 1
EA 4170 Malaria Research Unit
Faculty of Medicine
8 Avenue Rockefeller
69373 Lyon cedex 08, France

* Phone: 33 4 78 77 75 91 Fax: 33 4 78 77 72 29 E-mail: Anne-Lise.Bienvenu{at}recherche.univ-lyon1.fr

Antimicrobial Agents and Chemotherapy, November 2008, p. 4203-4204, Vol. 52, No. 11
0066-4804/08/$08.00+0     doi:10.1128/AAC.00513-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Helmers, A. J., Gowda, D. C., Kain, K. C., Liles, W. C. (2009). Statins Fail to Improve Outcome in Experimental Cerebral Malaria and Potentiate Toll-Like Receptor-Mediated Cytokine Production by Murine Macrophages. Am J Trop Med Hyg 81: 631-637 [Abstract] [Full Text]  
  • Parquet, V., Briolant, S., Torrentino-Madamet, M., Henry, M., Almeras, L., Amalvict, R., Baret, E., Fusai, T., Rogier, C., Pradines, B. (2009). Atorvastatin Is a Promising Partner for Antimalarial Drugs in Treatment of Plasmodium falciparum Malaria. Antimicrob. Agents Chemother. 53: 2248-2252 [Abstract] [Full Text]  
  • Wong, R. P. M., Davis, T. M. E. (2009). Statins as Potential Antimalarial Drugs: Low Relative Potency and Lack of Synergy with Conventional Antimalarial Drugs. Antimicrob. Agents Chemother. 53: 2212-2214 [Abstract] [Full Text]  

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bienvenu, A.-L.
Right arrow Articles by Picot, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bienvenu, A.-L.
Right arrow Articles by Picot, S.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»